Reason to trust
How Our News is Made
Strict editorial policy that focuses on accuracy, relevance, and impartiality
Ad discliamer
Morbi pretium leo et nisl aliquam mollis. Quisque arcu lorem, ultricies quis pellentesque nec, ullamcorper eu odio.
TL;DR
- KalshiEX has filed proposed listing standards for perpetual security futures tied to 58 stocks and ETFs.
- The proposal was published on September 18 under SEC File No. SR-KALSHIEX-2026-02.
- The products are not live; CFTC approval is still pending.
KalshiEX is seeking regulatory clearance for a product that would bring crypto-style perpetual futures mechanics into the US equity market.
A rule filing published by the SEC under File No. SR-KALSHIEX-2026-02 proposes listing standards for perpetual security futures tied to 58 stocks and exchange-traded funds.
Kalshi Targets Perpetual Exposure To Equities
Perpetual futures are already a core part of crypto trading, where contracts can remain open without a fixed expiration date and use funding mechanisms to keep prices aligned with the underlying market.
Applying a similar structure to US-listed stocks and ETFs would be a meaningful expansion of that model.
Kalshi’s filing establishes the proposed framework, but it does not make the contracts available for trading immediately.
The document explicitly notes that the CFTC has not yet approved the proposed rule change.
Filing Is A Regulatory Step, Not A Product Launch
That status is the most important limitation.
The products are not live, and the September 18 filing should not be presented as evidence that US equity perpetuals have already started trading on Kalshi.
Instead, the filing gives regulators and market participants a formal proposal to review.
If ultimately approved, the structure could blur some of the traditional boundaries between prediction-market infrastructure, derivatives exchanges and crypto-style perpetual trading.
For now, however, the confirmed story is procedural: KalshiEX has proposed perpetual security futures linked to 58 stocks and ETFs, and regulatory approval remains pending.
This article was written by the News Desk and edited by Samuel Rae.
